Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation | ||
By: Nasdaq / GlobeNewswire - 19 Jun 2018 | Back to overview list |
|
Data demonstrate CNDO-109-activated NK cells are safe, well tolerated and capable of extending complete remissions in high-risk acute myeloid leukemia patients NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from a Phase 1 clinical trial evaluating Fortress’ CNDO-109-activated allogeneic natural killer (NK) cells in acute myeloid leukemia (AML) patients have been published in the journal Biology of Blood and Marrow Transplantation. Todd A. Fehniger, M.D., Ph.D., Associate Professor of Medicine, Oncology Division at Washington University School of Medicine, and lead investigator on the Phase 1 trial, said, “This is an important early phase, dose-escalation trial that clearly identified the safety and feasibility of the innovative approach to prime donor NK cells with tumor cell lysates prior to adoptive transfer. The very durable responses that were achieved in several of the AML patients consolidated with CNDO-109-NK are exciting, and warrant further study in a larger number of patients.” The multi-center, non-randomized, open-label, dose-escalation Phase 1 trial evaluated the maximum tolerated dose of CNDO-109-activated NK cells in 12 adult AML patients in their first complete remission who were at a high risk of relapsing. Evaluation of the safety profile, the duration of relapse-free survival and overall survival were secondary objectives. CNDO-109-activated NK cells were prepared from a single leukapheresis product of peripheral blood mononuclear cells from a healthy, HLA-haploidentical first or second-degree relative. The NK (CD56+) cells were purified and incubated ex vivo with CNDO-109 lysate. Cytokines were not used in the incubation process. CNDO-109-activated NK cells were well tolerated, with no infusion-related adverse events or graft-versus-host disease reported. Three patients had long-term, relapse-free survivals of 32.6, 42.5+ and 47.6+ months after treatment, with two patients remaining relapse-free at the time of publication. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “We are encouraged by the early safety and efficacy profile demonstrated by CNDO-109-activated NK cells in AML patients, and look forward to continuing to advance the program.” The publication can be accessed on the Biology of Blood and Marrow Transplantation website at https://www.bbmt.org/article/S1083-8791(18)30132-0/fulltext. CNDO-109-Activated Allogeneic Natural Killer Cells About Acute Myeloid Leukemia About Fortress Biotech Forward-Looking Statements Company Contact: Investor Relations Contact: Media Relations Contact: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |